What Should Be Known Before Starting Weight Loss Injections?

Weight loss injections are among the medicine groups that have come up more frequently in weight management and obesity treatment in recent years. These medicines, which act through GLP-1 and similar mechanisms, are related to processes such as appetite control, satiety, delayed gastric emptying, and blood sugar regulation. The widespread discussion of medicine names such as Wegovy, Ozempic, Mounjaro, and similar medicines has increased interest in these treatments.

However, the most important point to know before starting weight loss injections is this: These medicines are not products to be started only with the desire to lose weight, social media advice, or someone else’s experience. Each medicine has a different licensing status, intended use, appropriate patient group, side effect profile, and follow-up requirement. Therefore, the weight loss injection process must be planned with physician evaluation, preferably under the follow-up of an endocrinologist.

Weight Loss Injection Is Not a Suitable Method for Everyone

Weight loss injections are not suitable for everyone who wants to lose weight. The use of these medicines should be evaluated according to many factors such as the person’s body mass index, waist circumference, metabolic risks, type 2 diabetes or insulin resistance status, thyroid history, pancreas and gallbladder history, kidney functions, medicines used, and pregnancy plan.

The World Health Organization defines overweight and obesity as abnormal or excessive fat accumulation that presents a risk to health. Therefore, weight management is not only an aesthetic issue; it is a medical process that should also be addressed in terms of cardiovascular health, blood sugar balance, hormone system, fatty liver, blood pressure, and general metabolic risks.

When evaluating the suitability of weight loss injections, the following headings should be considered:

• Body mass index
• Waist circumference and fat distribution
• Presence of type 2 diabetes or insulin resistance
• Hypertension, high cholesterol, or cardiovascular risk
• Thyroid disease and family history
• History of pancreatitis
• Gallstones or gallbladder disease
• Kidney and liver functions
• Prescription and non-prescription medicines used
• Pregnancy, breastfeeding, or pregnancy plan
• Previously tried weight management methods
• Eating behavior and dietary pattern
• Exercise habits and muscle mass status

Therefore, the decision for a weight loss injection should not be made only according to the number on the scale. The person’s metabolic health, accompanying diseases, and long-term follow-up needs should be evaluated together.

How Do GLP-1 Medicines Act?

GLP-1-related medicines may play a role in appetite, satiety, gastric emptying, and blood sugar control by mimicking the effects of some hormones naturally found in the body. These medicines may provide earlier fullness, less hunger, and reduced calorie intake in some people. This mechanism can support weight management; however, it also explains why gastrointestinal side effects may be seen.

In the Wegovy patient information leaflet published by the Turkish Medicines and Medical Devices Agency, it is stated that Wegovy contains the active ingredient semaglutide and resembles the naturally occurring hormone called GLP-1 in the body. This information shows that weight loss injections should not be considered simple “appetite suppressants,” but medical products that act on the metabolic system.

The effects of GLP-1-related medicines can generally be seen in the following areas:

• Decreased appetite
• Increased satiety
• Slowed gastric emptying
• Regulation of blood sugar response
• Support for weight management
• Helping with lower calorie intake
• Acting together with lifestyle changes

These effects are not seen in the same way in every person. While appetite decreases significantly in some people, side effects may be more dominant in others. Therefore, the treatment process should be planned individually.

Are Wegovy, Ozempic, and Mounjaro the Same?

In society, medicine names such as Wegovy, Ozempic, Mounjaro, and similar medicines are often discussed under the same heading. However, the active ingredients, intended uses, doses, licensing information, and appropriate patient groups of these medicines may be different. Therefore, it is not correct to consider all medicines the same under the expression “weight loss injection.”

Wegovy contains semaglutide and is considered a medicine used for chronic weight management in people who meet certain criteria. Ozempic also contains semaglutide; however, its main area of use is related to type 2 diabetes treatment. Mounjaro contains tirzepatide and is a medicine related to type 2 diabetes treatment. Zepbound is also a different product containing tirzepatide and coming into consideration in the field of weight management.

Medicine information that must be known before starting includes:

• Full name of the medicine
• Active ingredient
• Licensed intended use
• Which patient group it is suitable for
• Starting dose
• Dose escalation schedule
• Frequency of administration
• Conditions in which it should not be used
• Most common side effects
• Serious warnings
• Possibility of interaction with other medicines
• Pregnancy and breastfeeding information
• Storage conditions

It is not safe to start the medicine before this information is clarified. Even different products containing the same active ingredient may have different doses, different intended uses, and different follow-up requirements.

Why Is Physician Evaluation Essential?

The use of weight loss injections should not be a process decided by the person on their own. These medicines require follow-up in terms of the metabolic system, digestive system, blood sugar balance, and some special risk groups. Therefore, endocrinology evaluation is especially important before starting.

Endocrinology evaluation does not only mean “prescribing medicine.” Hormonal, metabolic, or lifestyle-related causes of excess weight may be investigated. Thyroid functions, blood sugar balance, insulin resistance, kidney and liver functions, lipid profile, accompanying diseases, and medicines used are evaluated together.

The main topics that should be addressed in physician evaluation are:

• Possible causes of excess weight
• Health risks accompanying obesity
• Type 2 diabetes or prediabetes status
• Thyroid diseases
• Insulin resistance
• Medicines used
• Previous diseases
• Family history of thyroid cancer or MEN 2
• Pancreatitis and gallbladder history
• Pregnancy plan
• Dietary pattern
• Physical activity level
• Treatment goals and follow-up plan

A treatment started without this evaluation may cause unnecessary medicine use, overlooked side effect risks, wrong medicine selection, or unrealistic weight loss expectations.

Which Health Information Should Be Shared Before Starting?

Before starting a weight loss injection, the person’s medical history should be shared clearly and completely. Some health conditions may require that the medicine not be used at all; some may require closer follow-up. Therefore, not only current weight information, but also general health history is important.

The person’s previous pancreatitis, gallbladder diseases, kidney problems, serious gastrointestinal disorders, thyroid diseases, and diabetes treatments must especially be evaluated. FDA product information includes warnings for GLP-1-related medicines regarding pancreatitis, gallbladder diseases, kidney functions, severe gastrointestinal reactions, hypoglycemia, and some thyroid tumor risks.

Information that must be reported to the physician before starting includes:

• Existing diseases
• Previous surgeries
• History of pancreatitis
• Gallstones or gallbladder surgery
• Thyroid nodule, thyroid cancer, or family history
• History of MEN 2
• Type 2 diabetes or low blood sugar episodes
• Kidney disease
• Liver disease
• Severe reflux, gastroparesis, or digestive system disease
• Prescription medicines used
• Supplements used
• Pregnancy, breastfeeding, or pregnancy plan
• Previously used weight loss medicines

Incomplete sharing of this information may affect treatment safety. The weight loss injection process should be planned together with personal health history.

Side Effects Should Be Known in Advance

Before starting a weight loss injection, it is important to be informed about possible side effects. The most common complaints with these medicines are generally related to the stomach and intestinal system. Nausea, vomiting, diarrhea, constipation, abdominal pain, indigestion, reflux, bloating, and decreased appetite may be seen.

Side effects may not always be mild. Severe vomiting or diarrhea may lead to dehydration. Severe and persistent abdominal pain may suggest problems related to the pancreas or gallbladder. The risk of low blood sugar may come into consideration in people using diabetes medicines. Therefore, which symptoms require consulting a physician should be discussed before treatment begins.

Common side effects that should be known before starting include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Indigestion
• Reflux
• Bloating
• Headache
• Fatigue
• Injection site reaction
• Decreased appetite

Symptoms that should be taken seriously are:

• Severe and persistent abdominal pain
• Abdominal pain radiating to the back
• Repeated vomiting
• Long-lasting diarrhea
• Significant decrease in urine amount
• Jaundice
• Severe weakness
• Symptoms of low blood sugar
• Shortness of breath or widespread allergic reaction
• Lump in the neck, hoarseness, or difficulty swallowing

If these symptoms develop, the person should not continue the medicine on their own, should not change the dose, and should consult a healthcare professional.

Dose Escalation Should Not Be Done on One’s Own

The dose plan in weight loss injections is very important for treatment safety. These medicines are generally started at a low dose and increased at certain intervals. Increasing the dose quickly may increase gastrointestinal side effects and make it difficult for the person to continue treatment.

It is risky for the person to increase the dose on their own in order to “lose weight faster.” A higher dose does not always mean a healthier or better result. The risk of side effects may increase, dehydration may develop, and the treatment process may become uncontrolled. Therefore, dose escalation should only be done according to the plan determined by the physician.

Points to consider during the dose process are:

• Starting with the recommended starting dose
• Not increasing the dose outside the physician’s plan
• Not increasing the dose without consulting the physician if side effects are present
• Not trying to compensate for missed doses
• Not using different GLP-1 medicines together
• Not using products containing the same active ingredient together
• Not applying someone else’s dose plan
• Paying attention to the medicine’s storage conditions
• Learning the injection administration instructions correctly

FDA product information states that some products containing semaglutide should not be used together with other semaglutide-containing products or other GLP-1 receptor agonists. This shows that medicine combinations must be evaluated under physician supervision.

The Risk of Counterfeit and Unlicensed Products Should Be Known

The increased interest in weight loss injections has also increased the risk of counterfeit and unlicensed products. Products obtained through the internet, social media accounts, personal recommendations, or unofficial sales channels may carry serious health risks. These products may contain no active ingredient, contain the wrong dose, or contain different substances harmful to health.

The World Health Organization has issued a medical product alert regarding falsified semaglutide products and emphasized that such products should only be obtained from authorized, licensed, and reliable supply channels. The FDA has also explained its safety concerns about the use of unapproved GLP-1 medicines for weight loss.

The risks of counterfeit or unlicensed products are:

• Receiving the wrong dose
• Using a product that does not contain the active ingredient
• Receiving an excessive dose
• Being exposed to a harmful or unknown substance
• Risk of injection-related infection
• Blood sugar imbalances
• Unexpected allergic reactions
• Treatment failure
• Side effects requiring urgent intervention

Therefore, weight loss injections should only be evaluated through legal, reliable, and physician-supervised channels. Products recommended through social media or with unclear sources should not be used.

Nutrition and Lifestyle Plan Should Be Ready

Before starting a weight loss injection, a nutrition and lifestyle plan should also be created. These medicines do not provide permanent weight management on their own. They may reduce appetite and support weight loss; however, diet quality, physical activity, preservation of muscle mass, sleep pattern, and behavior change are important for long-term success.

If only rapid results are targeted during the weight loss process, problems such as muscle loss, inadequate protein intake, vitamin-mineral deficiencies, weakness, and weight regain may occur. Therefore, before treatment begins, the person should set realistic goals, plan their dietary pattern, and be ready for the follow-up process.

Things that should be planned in terms of lifestyle before starting are:

• Individualized dietary pattern
• Adequate protein intake
• Fiber and fluid consumption
• Regular physical activity
• Exercise plan to preserve muscle mass
• Sleep pattern
• Stress management
• Reviewing alcohol and smoking use
• Weight follow-up
• Side effect follow-up
• Sustainable plan when treatment is stopped

The purpose of the medicine is not to move the person away from healthy habits, but to support weight management together with these habits in the appropriate person. Therefore, the treatment process should be planned holistically.

People With Diabetes Should Be Evaluated More Carefully

Weight loss injections have a different importance in people with type 2 diabetes. Some GLP-1-related medicines may also act on blood sugar regulation. This may be beneficial for some people; however, when used together with insulin or medicines that increase insulin secretion, the risk of low blood sugar may come into consideration.

FDA product information for tirzepatide-containing medicines such as Mounjaro draws attention to the risk of hypoglycemia when used together with insulin or insulin secretagogues. Therefore, the use of weight loss injections in people with diabetes should be planned by an endocrinologist; current medicines, blood sugar monitoring, and dietary pattern should be evaluated together.

People with diabetes should evaluate the following topics before starting:

• Current diabetes medicines
• Insulin use
• History of low blood sugar
• HbA1c level
• Home blood sugar monitoring
• Meal pattern
• Kidney functions
• History of diabetic retinopathy
• Recognizing symptoms of hypoglycemia
• How dose changes will be made

Treatment started without this evaluation may cause blood sugar fluctuations or medicine interactions.

Pregnancy, Breastfeeding, and Pregnancy Plan Must Be Discussed

Before starting a weight loss injection, pregnancy, breastfeeding, or pregnancy plan must be reported to the physician. These medicines are not products to be used for weight loss during pregnancy. If pregnancy is planned during treatment or pregnancy occurs, how the medicine will be managed should be evaluated with the physician.

FDA product information includes warnings for some GLP-1-related medicines such as Wegovy regarding discontinuation when pregnancy is recognized. Therefore, it is important for people of reproductive age to receive information about pregnancy plan, contraception method, and steps to be followed in the event of possible pregnancy before starting treatment.

Things to be evaluated in terms of pregnancy and breastfeeding are:

• Current pregnancy status
• Pregnancy plan in the near future
• Breastfeeding status
• Contraception method used
• The path to follow if pregnancy occurs during treatment
• When the medicine should be discontinued
• Safe alternatives before pregnancy for weight management

These topics should be discussed before treatment begins. The person should not decide on their own whether to stop or continue the medicine.

Why Are Thyroid and Pancreas History Important?

Before starting a weight loss injection, thyroid and pancreas history should be evaluated especially carefully. Some GLP-1-related medicines’ product information includes contraindications related to medullary thyroid carcinoma and MEN 2 history. These warnings do not mean that everyone who uses these medicines will develop thyroid cancer; however, they show that the medicine may not be suitable for people with risk history.

A history of pancreatitis is also important. GLP-1-related medicines include warnings about acute pancreatitis. Therefore, people who have previously had pancreatitis, have severe abdominal pain, or have a health condition requiring follow-up related to the pancreas must share this information with their physician.

The following information should especially be shared before starting:

• Family history of medullary thyroid cancer
• Personal history of thyroid cancer
• Diagnosis or suspicion of MEN 2
• Thyroid nodule or followed thyroid disease
• Previous pancreatitis
• History of severe and recurrent abdominal pain
• Gallstones or gallbladder surgery
• Unexplained digestive system complaints

This information may directly affect the suitability of the medicine and the follow-up plan.

Expectations Should Be Realistic

Before starting a weight loss injection, expectations must be realistic. These medicines may support significant weight loss in some people; however, not everyone loses weight at the same speed and in the same amount. Weight loss may vary according to medicine dose, treatment adherence, dietary pattern, physical activity, metabolic status, sleep, stress, and accompanying diseases.

In addition, rapid weight loss does not always mean healthy weight loss. Very rapid weight loss may lead to muscle loss, gallbladder problems, weakness, and sustainability problems. The aim of treatment is not only to lose weight in a short time, but to support long-term metabolic health.

Expectations that should be clarified before starting are:

• Weight loss goal
• Treatment duration
• Follow-up frequency
• Possible side effects
• Adherence to nutrition plan
• Exercise goal
• Speed of weight loss
• Plan after stopping the medicine
• Strategies to prevent weight regain
• Follow-up of metabolic indicators

When these expectations are set correctly, the person can manage the treatment process more consciously. Otherwise, the expectation of quick results may cause uncontrolled dose escalation or incorrect use of treatment.

Questions to Ask Before Starting a Weight Loss Injection

Before starting the weight loss injection process, it is useful for the person to ask their physician some basic questions. These questions help better understand the suitability of the medicine and the follow-up plan. Asking questions before starting treatment allows the person to use the medicine more consciously.

Questions that can be asked to the physician are:

• Is this medicine really necessary for me?
• Which active ingredient is more suitable for my condition?
• What is the licensed intended use of the medicine?
• Which dose will be started?
• When and how will the dose be increased?
• Which side effects can be considered normal?
• Which symptoms require urgent evaluation?
• If I have diabetes medicines, will dose adjustment be needed?
• Do I have risks related to thyroid, pancreas, or gallbladder?
• Which blood tests should be followed?
• How often should follow-up be done?
• How long do I need to use the medicine?
• How can weight regain be prevented if I stop the medicine?
• How should my nutrition and exercise plan be?
• What should I do if I have a pregnancy plan?

The answers to these questions are individual. Therefore, general information obtained from the internet is not enough to make a decision.

Weight Loss Injection Should Be Planned With Medical Follow-Up

The most important step before starting weight loss injections is evaluating whether the person is suitable for this treatment. GLP1, Wegovy, Mounjaro, Ozempic, or similar medicines are medicines that affect the metabolic system and have side effects and follow-up requirements. Therefore, they should not be used with promises of rapid weight loss, social media recommendations, or someone else’s prescription.

The correct approach is to evaluate the person’s health history, metabolic risks, current medicines, weight management goals, and lifestyle together. A weight loss injection should only be started after this holistic evaluation, if considered appropriate, and with a regular follow-up plan.

Access Online Endocrinology Doctor Support With Happ Health

Before starting a weight loss injection, it is important to know whether the medicine is suitable for you, which risks need to be evaluated, and how you will be followed during the treatment process. When GLP1, Wegovy, Mounjaro, Ozempic, or similar medicines come into consideration, endocrinology evaluation can help the process progress more safely and consciously.

Happ Health, with its digital health platform approach, offers a solution that makes access to Online Endocrinology Doctor support easier. You can receive expert opinion within the scope of remote healthcare service about weight management, metabolic risks, hormone balance, blood sugar status, and suitability for weight loss injections; and plan the process more correctly before starting treatment.

References

• World Health Organization. Obesity and overweight.
  https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
• World Health Organization. Obesity.
  https://www.who.int/health-topics/obesity/
• World Health Organization. Medical Product Alert N°2/2024: Falsified OZEMPIC (semaglutide).
  https://www.who.int/news/item/19-06-2024-medical-product-alert-n-2-2024--falsified-ozempic-%28semaglutide%29
• U.S. Food and Drug Administration. Wegovy Prescribing Information.
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf
• U.S. Food and Drug Administration. Mounjaro Prescribing Information.
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
• U.S. Food and Drug Administration. Zepbound Prescribing Information.
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf
• U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
  https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
• Turkish Medicines and Medical Devices Agency. Wegovy Patient Information Leaflet.
  https://www.titck.gov.tr/storage/Archive/2025/kubKtAttachments/WEGOVY1KT_17_02_2025.pdf
• Turkish Medicines and Medical Devices Agency. Wegovy Summary of Product Characteristics.
  https://www.titck.gov.tr/storage/Archive/2025/kubKtAttachments/WEGOVY1KB_17_02_2025.pdf